Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Veru had a pre-IND meeting with the FDA Division ... In fact, the safety section of the package insert for Wegovy has been updated based on the recently reported SELECT cardiovascular outcomes ...

Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

Veru had a pre-IND meeting with the FDA Division of Cardiology ... In fact, the safety section of the package insert for Wegovy has been updated based on the recently reported SELECT cardiovascular ...

Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...